Joanna Richey

Learn More
Despite clinical approval of erlotinib, most advanced lung cancer patients are primary non-responders. Initial responders invariably develop secondary resistance, which can be accounted for by T790M-EGFR mutation in half of the relapses. We show that MET is highly expressed in lung cancer, often concomitantly with epidermal growth factor receptor (EGFR),(More)
  • Kathy Coronetz, Dave Galvin, Elsie Hulsizer, Steve Klusman, Butch Lovelace, Josh Marx +54 others
  • 2004
FROM THE DNRP MANAGEMENT TEAM This report reflects our determination to improve how we measure our performance and use performance information to improve the environment and quality of life in King County. It is also part of a larger effort to communicate our accomplishments and broaden the dialogue with our elected officials and residents. As part of this(More)
  • 1